Confidential documents obtained in antidepressant litigation in the United States and released into the public domain have revealed pharmaceutical industry misconduct, including exposure of hidden risks and overblown efficacy, selective reporting of efficacy and safety, conflicts of interests and rampant ghostwriting of medical journal articles for marketing purposes. [Source]
Fid
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
No comments: